Va. Skoutakis et al., COMPARATIVE ROLE OF OMEPRAZOLE IN THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE, The Annals of pharmacotherapy, 29(12), 1995, pp. 1252-1262
OBJECTIVE: TO review gastroesophageal reflux disease (GERD) and its tr
eatment, with emphasis on the use and place of omeprazole, a proton pu
mp inhibitor. DATA SOURCES: A compilation prepared by the National Lib
rary of Medicine's Interactive Retrieval Services (Medlars II) for the
period 1987 to 1994 was used as the data source. STUDY SELECTION: Foc
us was placed on human comparative clinical studies with well-accepted
measures of esophageal healing (endoscopy) and symptom resolution. Sa
fety data were compiled from the clinical trials literature and large
postmarketing data studies. Pharmacoeconomic studies selected were jud
ged to meet the criteria of good design, presence of sensitivity testi
ng, and statement of perspective. DATA EXTRACTION: Data were obtained
from double-blind, controlled clinical studies. Other data were extrac
ted from pertinent literature of good design and significant results.
DATA SYNTHESIS: Overall, the clinical trials of omeprazole for the tre
atment of patients with erosive GERD demonstrate that omeprazole provi
des superior therapy in terms of esophageal healing symptom resolution
and patient compliance when compared with histamine(2)-receptor antag
onists (H(2)RAs) and antacids. In addition, studies also indicate that
omeprazole is the most effective agent for the treatment of patients
with GERD refractory to other treatments. Dosage adjustment is not nec
essary in patients with impaired renal or hepatic function or in the e
lderly, Finally, although the acquisition drug cost for daily treatmen
t of patients with GERD is highest with the use of omeprazole, pharmac
oeconomic studies indicate that treatment is more cost-effective with
the use of omeprazole than with H(2)RA or antacid treatment alone or c
ombined with nonpharmacologic approaches. CONCLUSIONS: Based on effica
cy, safety, and cost-effectiveness, omeprazole is the drug of choice f
or the treatment of patients with endoscopically confirmed erosive GER
D.